Feng Liu, Lei Wang, Xiao Ying Li
Mar 1, 2011
Citations
5
Influential Citations
86
Citations
Quality indicators
Journal
Journal of Gastroenterology and Hepatology
Abstract
Background and Aims: Lamivudine, a nucleoside analog, is commonly used for treatment of chronic hepatitis B (CHB) but its durability of effectiveness after withdrawal is still uncertain. This study was designed to assess the durability of lamivudine treatment with stringent cessation criteria in hepatitis B e antigen (HBeAg)‐negative patients and to explore potential predictive factors.